Randomized Double-blind Study on the Treatment of Osteoarthritis of the Bilateral Knee: Autologous Bone Marrow Concentrate vs. Hyaluronic Acid
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Osteoarthritis, Knee
- Sponsor
- Istituto Ortopedico Rizzoli
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- International Knee Documentation Committee (IKDC)-Subjective score
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
OA-bi-Blind is a randomized double-blind study on the treatment of osteoarthritis of the Bilateral knee: autologous bone marrow concentrate vs. hyaluronic acid.
Detailed Description
a randomized, controlled, double-blind study and we will be evaluated and compared the clinical and radiological results of concentrated autologous bone marrow against the hyaluronic acid in patients with bilateral knee osteoarthrosis . In randomization, one knee will be treated with autologous bone marrow concentrate and other knee with hyaluronic acid, then every patient is considered both in control and treatment group, limiting the heterogenity between groups and will not be informed of the knee assigned to the treatment group.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female patients, aged between 18 and 75 years;
- •Bilateral symptomatic knee osteoarthritis (Kellgren-Lawrence grade 1-4);
- •Failure after two months of conservative treatment;
- •Capacity and consent of patients to participate actively in the rehabilitation protocol, follow-up clinic and radiology protocol;
- •Signature of informed consent.
Exclusion Criteria
- •Patients incapable of discernment;
- •Patients with malignancy
- •Patients with rheumatic diseases;
- •Patients with diabetes;
- •Patients with metabolic disorders of the thyroid;
- •Patients belonging abuse of alcohol, drugs or medications;
- •Patients with misalignment of the lower limbs than 10 °;
- •Body Mass Index\> 40;
- •Patients with a history of trauma or intra-articular infiltration of therapeutic substances within 6 months prior to treatment.
Outcomes
Primary Outcomes
International Knee Documentation Committee (IKDC)-Subjective score
Time Frame: Time Frame: 6 months
Clinical improvement, measured by the change in scores IKDC Subjective
Secondary Outcomes
- International Knee Documentation Committee (IKDC)-Subjective score(Time Frame: 1,3,6, 12, 24 months evaluation)
- Knee Injury and Osteoarthritis Outcome Score (KOOS).(Time Frame: 1,3,6, 12, 24 months evaluation)